Cargando…

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation

Starting from the beginning of the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) global pandemic, most of the published data has concentrated on the respiratory signs and symptoms of Covid-19 infection, underestimating the presence and importance of ocular manifestations, such as conj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zauli, Giorgio, AlHilali, Sara, Al-Swailem, Samar, Secchiero, Paola, Voltan, Rebecca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329687/ https://www.ncbi.nlm.nih.gov/pubmed/35911386 http://dx.doi.org/10.3389/fmed.2022.902713

Ejemplares similares

MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
por: Romani, Arianna, et al.
Publicado: (2022)

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
por: Tisato, Veronica, et al.
Publicado: (2017)

Challenges of Glaucoma Management in Patients with Type I Boston Keratoprosthesis
por: AlHilali, Sara M, et al.
Publicado: (2022)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Acute Sterile Keratolysis After Deep Anterior Lamellar Keratoplasty in a Patient With Keratoconus: A Case Report
por: Al-Swailem, Samar A., et al.
Publicado: (2023)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
por: Rimondi, Erika, et al.
Publicado: (2021)

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3
por: Agnoletto, Chiara, et al.
Publicado: (2014)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Impact and Determinants of COVID-19 Pandemic on the Cataract Surgery Rate at a Tertiary Referral Center
por: AlHilali, Sara, et al.
Publicado: (2022)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells
por: Lodi, Giada, et al.
Publicado: (2022)

Clinical perspectives of TRAIL: insights into central nervous system disorders
por: Tisato, Veronica, et al.
Publicado: (2016)

State of the Art of Pharmacological Activators of p53 in Ocular Malignancies
por: Casciano, Fabio, et al.
Publicado: (2023)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics)
por: Milani, Daniela, et al.
Publicado: (2022)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Palmitic Acid Induced a Long-Lasting Lipotoxic Insult in Human Retinal Pigment Epithelial Cells, which Is Partially Counteracted by TRAIL
por: Sergi, Domenico, et al.
Publicado: (2022)

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
por: Kaindl, U, et al.
Publicado: (2014)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?
por: Bernardi, Stella, et al.
Publicado: (2019)

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
por: Zauli, Giorgio, et al.
Publicado: (2020)

The p53 transcriptional pathway is preserved in ATM(mutated) and NOTCH1(mutated) chronic lymphocytic leukemias
por: Athanasakis, Emmanouil, et al.
Publicado: (2014)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Splinter Cataract in Patients with Keratoconus and Frequent Eye Rubbing: A Novel Finding
por: Kirat, Omar, et al.
Publicado: (2023)

In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure
por: Voltan, Rebecca, et al.
Publicado: (2014)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol
por: Zajkowicz, Artur, et al.
Publicado: (2013)

Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1
por: Voltan, Rebecca, et al.
Publicado: (2016)

Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells
por: Tisato, Veronica, et al.
Publicado: (2014)

HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts
por: Trapella, Claudio, et al.
Publicado: (2018)

Author Correction: HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts
por: Trapella, Claudio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4qh2hanq9k38u9jepmu1dr6m0k